Becton, Dickinson and Company $BDX Stock: Kintegral Advisory LLC Raises Stake

Kintegral Advisory LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 46.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,684 shares of the medical instruments supplier’s stock after purchasing an additional 2,749 shares during the quarter. Kintegral Advisory LLC’s holdings in Becton, Dickinson and Company were worth $1,554,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the business. Vontobel Holding Ltd. lifted its position in Becton, Dickinson and Company by 27.5% during the 3rd quarter. Vontobel Holding Ltd. now owns 116,608 shares of the medical instruments supplier’s stock worth $20,873,000 after buying an additional 25,121 shares in the last quarter. TD Waterhouse Canada Inc. increased its position in Becton, Dickinson and Company by 35.2% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 130,042 shares of the medical instruments supplier’s stock valued at $23,278,000 after acquiring an additional 33,831 shares in the last quarter. ARS Wealth Advisors Group LLC increased its position in Becton, Dickinson and Company by 2.9% in the 3rd quarter. ARS Wealth Advisors Group LLC now owns 30,255 shares of the medical instruments supplier’s stock valued at $5,416,000 after acquiring an additional 852 shares in the last quarter. Rise Advisors LLC acquired a new stake in Becton, Dickinson and Company in the 3rd quarter valued at about $51,000. Finally, Pension & Wealth Management Advisors Inc. raised its stake in shares of Becton, Dickinson and Company by 12.3% in the third quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock worth $94,000 after acquiring an additional 56 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of a number of research reports. TD Cowen upped their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Bank of America raised their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Monday, August 31st. Barclays started coverage on shares of Becton, Dickinson and Company in a research report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price objective for the company. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Finally, Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Seven analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $185.07.

Becton, Dickinson and Company Trading Down 1.3%

Becton, Dickinson and Company stock traded down $2.42 during trading hours on Friday, reaching $191.34. 1,412,670 shares of the company’s stock traded hands, compared to its average volume of 1,816,545. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $195.99. The firm has a market capitalization of $52.72 billion, a price-to-earnings ratio of 57.63, a PEG ratio of 13.06 and a beta of 0.21. The firm’s 50 day moving average is $184.03 and its 200-day moving average is $163.70.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the company earned $3.68 EPS. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were paid a $1.05 dividend. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 6,906 shares of company stock valued at $1,265,855. 0.40% of the stock is currently owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.